Follow-up FDG PET/CT in Patients with Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management

Mehdi Taghipour, Charles Marcus, Pratyusha Nunna, Rathan M. Subramaniam

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). Patients and Methods All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Results Among the 560 scans, 388 scans (69.3%) were done without clinical suspicion and 172 scans (30.7%) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4% of the scans performed without clinical suspicion and ruled out disease in 16.3% scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8% of follow-up scans with prior clinical suspicion of recurrence and after 8.3% of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6% scans with prior clinical suspicion of recurrence of which 23.3% had no treatment before and after the scan and 27.3% had the same treatment continued before and after the scan. Conclusions Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3% of the scan times and influenced the management in 37.8% of scan times. The management change was only 8.3% in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.

Original languageEnglish (US)
Pages (from-to)e93-e97
JournalClinical Nuclear Medicine
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Non-Hodgkin's Lymphoma
Recurrence
Time Management
Therapeutics

Keywords

  • CT
  • follow-up
  • non-Hodgkin lymphoma
  • PET
  • survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Follow-up FDG PET/CT in Patients with Non-Hodgkin Lymphoma : Value to Clinical Assessment and Patient Management. / Taghipour, Mehdi; Marcus, Charles; Nunna, Pratyusha; Subramaniam, Rathan M.

In: Clinical Nuclear Medicine, Vol. 41, No. 2, 01.02.2016, p. e93-e97.

Research output: Contribution to journalArticle

@article{8e5491d928f540d697391a7f0b083ed0,
title = "Follow-up FDG PET/CT in Patients with Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management",
abstract = "Objective The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). Patients and Methods All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Results Among the 560 scans, 388 scans (69.3{\%}) were done without clinical suspicion and 172 scans (30.7{\%}) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4{\%} of the scans performed without clinical suspicion and ruled out disease in 16.3{\%} scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8{\%} of follow-up scans with prior clinical suspicion of recurrence and after 8.3{\%} of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6{\%} scans with prior clinical suspicion of recurrence of which 23.3{\%} had no treatment before and after the scan and 27.3{\%} had the same treatment continued before and after the scan. Conclusions Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3{\%} of the scan times and influenced the management in 37.8{\%} of scan times. The management change was only 8.3{\%} in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.",
keywords = "CT, follow-up, non-Hodgkin lymphoma, PET, survival",
author = "Mehdi Taghipour and Charles Marcus and Pratyusha Nunna and Subramaniam, {Rathan M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1097/RLU.0000000000001034",
language = "English (US)",
volume = "41",
pages = "e93--e97",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Follow-up FDG PET/CT in Patients with Non-Hodgkin Lymphoma

T2 - Value to Clinical Assessment and Patient Management

AU - Taghipour, Mehdi

AU - Marcus, Charles

AU - Nunna, Pratyusha

AU - Subramaniam, Rathan M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). Patients and Methods All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Results Among the 560 scans, 388 scans (69.3%) were done without clinical suspicion and 172 scans (30.7%) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4% of the scans performed without clinical suspicion and ruled out disease in 16.3% scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8% of follow-up scans with prior clinical suspicion of recurrence and after 8.3% of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6% scans with prior clinical suspicion of recurrence of which 23.3% had no treatment before and after the scan and 27.3% had the same treatment continued before and after the scan. Conclusions Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3% of the scan times and influenced the management in 37.8% of scan times. The management change was only 8.3% in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.

AB - Objective The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). Patients and Methods All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Results Among the 560 scans, 388 scans (69.3%) were done without clinical suspicion and 172 scans (30.7%) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4% of the scans performed without clinical suspicion and ruled out disease in 16.3% scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8% of follow-up scans with prior clinical suspicion of recurrence and after 8.3% of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6% scans with prior clinical suspicion of recurrence of which 23.3% had no treatment before and after the scan and 27.3% had the same treatment continued before and after the scan. Conclusions Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3% of the scan times and influenced the management in 37.8% of scan times. The management change was only 8.3% in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.

KW - CT

KW - follow-up

KW - non-Hodgkin lymphoma

KW - PET

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84955202467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955202467&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001034

DO - 10.1097/RLU.0000000000001034

M3 - Article

C2 - 26545018

AN - SCOPUS:84955202467

VL - 41

SP - e93-e97

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -